Company: HMDCF
Filing Date: 2025-03-19
Form Type: 20-F
Source: 0001410578-25-000377
Chunk: 578

Company: HUTCHMED (China) Ltd
Filing Date: 2025-03-19
Form: 20-F
Item: Item 6
Chunk 578
---
 workshops for drug product supply, with technology transfers completed for all clinical supplies; manufacturing and delivering substantial numbers of batches of Fruzaqla to Takeda; establishing additional infrastructure to control cost, quality and scheduling of drug substance supplies.
Commercial and financial goals. Reported total oncology product revenue of $272 million, including revenue from Elunate, Sulanda and Tazverik – the three medicines marketed by the HUTCHMED commercial team – of $136 million, and triggered regulatory and sales milestone payments from Takeda of $35 million; and in particular, reported net income of $38 million given that the 2023 net income of $101 million included the recognition of $280 million from the upfront payment from the license agreement with Takeda.
Business development and alliance management goals. Signed agreements to substantially divest interest in the Shanghai Hutchison Pharmaceuticals joint venture for approximately $608 million; managed new alliance with Takeda to launch Fruzaqla, and continued to manage alliance with AstraZeneca on Orpathys.
Organization. Reorganized group following ex-China partnership with Takeda, including right-sizing ex-China resources and further steps to focus on optimizing efficiency, controlling cost and risk management. Also certified as a Top Employer in 2024, which is based on a comprehensive analysis of the Company’s Human Resources environment, in alignment with the Company’s goals in creating a great place to work.
Sustainability. progress made in the 11 short- to long-term goals and targets; enhanced climate actions, including an assessment on the potential financial impacts of climate risks and opportunities for HUTCHMED, in-line with new disclosure requirements; conducted a biodiversity assessment and added a Biodiversity Policy; conduced a supplier ESG assessment; improved ESG ratings, including upgrades by MSCI ESG from BBB to A, by S&P Global from a score of 48 to 53, and reaching A- rating and a top quartile score in the Hang Seng Corporate Sustainability Index Series rating. Also received multiple ESG awards in 2024.
​

Remuneration components 
The goal of our remuneration programs is to align remuneration delivery with performance, measured both internally against budgets and key operational achievements, and externally through share price. We believe this alignment was achieved in 2024. 
In general, our compensation consists of the following components:

●   Base salary, to attract and retain highly skilled talent. This fixed component of pay is to provide financial stability, based on responsibilities